Antibiotic treatment of Lyme borreliosis: What is the evidence?

Annals of the Rheumatic Diseases

Volumn 64, Issue 4, 2005, Pages 519-523

  Dinser, R ^a   Jendro, M C ^a   Schnarr, S ^b   Zeidler, H ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BENZATHINE PENICILLIN; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; DOXYCYCLINE; ERYTHROMYCIN; MINOCYCLINE; PENICILLIN DERIVATIVE; PENICILLIN G; PENICILLIN V; PLACEBO; PROBENECID; TETRACYCLINE;

ANTIBIOTIC THERAPY; BACTERIAL ARTHRITIS; BORRELIA; BORRELIA INFECTION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; ERYTHEMA CHRONICUM MIGRANS; EVIDENCE BASED MEDICINE; HUMAN; LYME DISEASE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; ARTHRITIS, INFECTIOUS; DISEASE PROGRESSION; ERYTHEMA CHRONICUM MIGRANS; EVIDENCE-BASED MEDICINE; HUMANS; LYME DISEASE;

EID: 16344369559     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.027367     Document Type: Review

References (55)

1. Steere AC, Malawista SE, Newman JH, Spieler PN, Bartenhagen NH. Antibiotic therapy in Lyme disease. Ann Intern Med 1980;93:1-8.
2. Dattwyler RJ, Volkman DJ, Conaty SM, Platkin SP, Luft BJ. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet 1990;336:1404-6.
3. Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP. Comparison of ceruroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 1992;117:273-80.
4. Wormser GP, Ramanathan R, Nowakowski J, McKenna D, Holmgren D, Visintainer P, et al. Duration of antibiotic therapy for early Lyme disease. Ann Intern Med 2003;138:697-704.
5. Luft BJ, Dattwyler RJ, Johnson RC, Luger SW, Bosler EM, Rahn DW, et al. Azithromycin compared with amoxicillin in the treatment of erythema migans. Ann Intern Med 1996;124:785-91.
6. Weber K, Neubert U. Clinical features of early erythema migrans disease and related disorders. Zbl Bakt Hyg [A] 1986;263:209-28.
7. Weber K, Preac-Mursic V, Wilske B, Thurmayr R, Neubert U, Scherwitz C. A randomized trial of ceftriaxone versus oral penicillin for the treatment of early European Lyme borreliosis. Infection 1990;18:91-6.
8. Weber K, Wilske B, Preac-Mursic V, Thurmayr R. Azithromycin versus penicillin V for the treatment of early Lyme borreliosis. Infection 1993;21:367-72.
9. Strie F, Preac-Mursic V, Cimperman J, Ruzic E, Maraspin V, Jereb M. Azithromycin versus doxycyclin for treatment of erythema migrans: clinical and microbiological findings. Infection 1993;21:83-8.
10. Barsic B, Maretic T, Majerus L, Strugar J. Comparison of azithromycin and doxycycline in the treatment of erythema migrans. infection 2000;28:153-6.
11. Breier F, Kunz G, Klade H, Stanek G, Aberer E. Erythema migrans: three weeks treatment for prevention of late Lyme borreliosis. Infection 1996;24:69-72.
12. Strle F, Nadelman RB, Cimperman J, Nowakoski J, Picken RN, Schwartz I, et al. Comparison of culture-confirmed erythema migrans caused by borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia. Ann Intern Med 1999;130:32-6.
13. Balmelli T, Piffaretti JC. Association between different clinical manifestations of Lyme disease and different species of borrelia burgdorferi sensu lato. Res Microbiol 1995;146:329-40.
14. Steere AC, Green J, Schoen RT, Taylor E, Hutchinson GJ, Rahn DW, et al. Successful parenteral penicillin therapy of established Lyme arthritis. N Engl J Med 1985;312:869-74.
15. Caperton EM, Helm-Duthoy KL, Matzke GR, Peterson PK, Johnson RC. Ceftriaxone therapy of chronic inflammatory arthritis. Arch intern Med 1990;150:1677-82.
16. Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ. Treatment of late Lyme borreliosis-randomised comparison of ceftriaxone and penicillin. Lancet 1988;8596:1191-4.
17. Steere AC, Levin RE, Molloy PJ, Kalish RA, Abraham JH, Liu NY, et al. Treatment of Lyme arthritis. Arthritis Rheum 1994;37:878-88.
18. Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987;107:725-31.
19. Steere AC. Lyme disease. N Engl J Med 2001;345:115-25.
20. Valesova H, Mailer J, Havlik J, Hulinska D, Hercogova J. Long-term results in patients with Lyme arthritis following treatment witn ceftriaxone. Infection 1996;24:98-102.
21. Hassler D, Zöller L, Haude M, Hufnagel HD, Heinrich F, Sonntag HG. Cefotaxime versus penicillin in the late stage of Lyme disease-prospective randomized therapeutic study. Infection 1990;18:16-20.
22. Bentas W, Karch H, Huppertz HI. Lyme arthritis in children and adolescents: outcome 12 months after initiation of antibiotic therapy. J Rheumatol 2000;27:2025-30.
23. Jaulhac B, Heller R, Limbach FX, Hansmann Y, Lipsker D, Monteil H, et al. Direct molecular typing of borrelia burgdorferi sensu lato species in synovial samples from patients with Lyme arthritis. J Clin Microbiol 2000;38:1895-900.
24. Lünemann JD, Zarmas S, Priem S, Franz J, Zschenderlein R, Aberer E, et al. Rapid typing of borrelia burgdorferi sensu lato species in specimens from patients with different manifestations of Lyme borreliosis. J Clin Microbiol 2001;39:1130-3.
25. Nocton JJ, Dressier F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med 1994;330:229-34.
26. Hulinska D, Votypka J, Valesova M. Persistence of borrelia garinii and borrelia afzelii in patients with lyme arthritis. Zbl Bakt 1999;289:301-18.
27. Carlson D, Hernandez J, Bloom BJ, Coburn J, Aversa JM, Steere AC. Lack of borrelia burgdorferi DNA in synovial samples from patients with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum 1999;42:2705-9.
28. Brown CR, Reiner SL. Clearance of borrelia burgdorferi may not be required for resistance to experimental lyme arthritis. Infect Immun 1998;66:2065-7.
29. Steere AC, Glickstein L. Elucidation of Lyme arthritis. Nature Rev 2004;4:143-52.
30. Schnarr S, Putschky N, Jendro MC, Zeidler H, Hammer M, Kuipers JG, et al. Chlamydia and borrelia DNA in synovial fluid of patients with early undifferentiated oligoarthritis. Arthritis Rheum 2001;44:2679-85.
31. Wormser GP, Nadelman RB, Dattwyler RJ, Dennis DT, Shapiro ED, Steere AC, et al. Practice guidelines for the treatment of Lyme disease. Clin Infect Dis 2000;31(suppl 1):S1-14.
32. Clark JR, Carlson RD, Sasaki CT, Pachner AR, Steere AC. Facial paralysis in Lyme disease. Laryngoscope 1985;95:1341-5.
33. Steere AC, Batsford WP, Weinberg M, Alexander J, Berger HJ, Wolfson S, et al. Lyme carditis: cardiac abnormalities of Lyme disease. Ann Intern Med 1980;93:8-16.
34. Hansen K, Lebech AM. The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985-1990. A prospective study on 187 patients with Borrelia burgdorferi specific intrathecal antibody production. Brain 1992;115:399-423.
35. Mister HW, Preac-Mursic V, Wilske B, Einhaupl KM. Cefotaxime vs penicillin G for acute neurologic manifestations of Lyme borreliosis. A prospective randomised study. Arch Neurol 1989;46:1190-4.
36. Karlsson M, Hammers-Berggren S, Lindquist L, Stiernstedt G, Svenungsson B. Neurology 1994;44:1203-7.
37. Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med 1990;323:1438-44.
38. Kindstrand E, Nilsson BY, Hovmark A, Pirskanen R, Asbrink E. Peripheral neuropathy in acrodermatitis chronica afrophicans-effect of treatment. Acta Neurol Scand 2002;106:253-7.
39. Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001;345:85-92.
40. Gerber MA, Shapiro ED, Burke GS, Parcells VJ, Bell GL. Lyme disease in children in southeastern conneticut. N Engl J Med 1996;335:1270-4.
41. Plörer A, Sepp N, Schmurzhard E, Krabichler S, Trobos S, Schauer G, et al. Effects of adequate versus inadequate treatment of cutaneous manifestations of Lyme borreliosis on the incidence of late complications and late serologic status. J Invest Dermatol 1993;100:103-9.
42. Seltzer EG, Gerber MA, Cartter ML, Freudigman K, Shapiro, eds. Long-term outcome of persons with Lyme disease. JAMA 2000;283:609-16.
43. Asbrink E, Olsson I, Hovmark A. Erythema chronicum migrons afzelius in Sweden. A study on 231 patients. Zbl Bakt Hyg (A) 1986;263:229-36.
44. Huppertz HI, Karch H, Suschke HJ, During E, Ganser G, Thon A, et al. Lyme arthritis in European children and adolescents. Arthritis Rheum 1995;38:361-8.
45. Huppertz HI, Böhme M, Standaert SM, Karch H, Plotkin SA. Incidence of Lyme borreliosis in the Würzburg region of Germany. Eur J Clin Microbiol Infect Dis 1999;18:697-703.
46. Priem S, Munkelt K, Franz JK, Schneider U, Werner T, Burmester GR, et al. Epidemiologie und Therapie der Lyme-Arthritis und anderer Manifestationen der Lyme-Borreliose in Deutschland. Z Rheumatol 2003;62:450-8.
47. Münchhoff P, Wilske B, Preac-Mursic V, Schierz G. Antibodies against borrelia burgdorferi in Bavarian forest workers. Zbl Bakt Hyg [A] 1987;263:412-19.
48. Fahrer H, Sauvain MJ, Zhioua E, van Hoecke C, Gern LE. Longterm survey (7 years) in a population at risk for Lyme borreliosis: what happens to the seropositive individuals? Eur J Epidemiol 1998;14:117-23.
49. Zhioua E, Gern L, Aeschlimann A, Sauvain MJ, van der Linden S, Fahrer H. Longitudinal study of Lyme borreliosis in a high risk population in Switzerland. Parasite 1998;5:383-6.
50. Öhme R, Hartelt K, Backe H, Brockmann S, Kimmig P. Foci of tick-borne diseases in southwest Germany. Int J Med Microbiol, 2002;291(Suppl), 33:22-9.
51. Kaiser R, Kern A, Kampa D, Neumann-Haefelin D. Prevalence of antibodies to borrelia burgdorferi and tick-borne encephalitis virus in an endemic region in southern Germany. Zbl Bakt 1997;286:534-41.
52. Maiwald M, Öhme R, March O, Petney TN, Kimmig P, Naser K, et al. Transmission risk of borrelia burgdorferi sensu lato from ixodes ricinus ticks to humans in southwest Germany. Epidemiol Infect 1998;121:103-8.
53. Rauter C, Öhme R, Diterich I, Engele M, Hartung T. Distribution of clinically relevant borrelia genospecies in ticks assessed by a novel, single-run, real-time PCR. J Clin Microbiol 2002;40:36-43.
54. Reid MC, Schoen TR, Evans J, Rosenberg JC, Horwirz RI. The consequences of overdiagnosis and overtreatment of Lyme disease. Ann Intern Med 1998;128:354-62.
55. Sieper J, Fendler C, Laitko S, Sorensen H, Grippenberg-Lerche C, Hiepe F, et al. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomised, placebo-controlled study. Arthritis Rheum 1999;42:1386-96.